title: Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas.
abstract: Forty-one patients with prolactinoma (25 micro-, 16 macroprolactinomas) were treated with a long-acting injectable preparation of bromocriptine (Parlodel LAR, Sandoz), 25-100 mg (mostly 50 mg) in every 4-8 weeks for as long as 43 months (median 19 months). The first injection caused a prompt fall of plasma PRL which reached its nadir value after 3 days. Thereafter, hormone levels remained well below initial values for 4 weeks or longer, though with the tendency, more pronounced in microprolactinoma patients, to rise again toward baseline. The prevalence of PRL normalization was greater in the macro- than in the microprolactinoma group. By repeated injections plasma PRL could be kept close to or within the normal limits in most of the patients. However, the extent of PRL inhibition was significantly greater in macro- than in microprolactinoma patients (p less than 0.01). Clinical improvement occurred in the majority of the patients, shrinkage of the tumour in 50% of them. Adverse reactions were generally mild or of moderate severity and subsided spontaneously in 24 h. They were less frequent (NS) and less severe (p less than 0.05) in macro- than in microprolactinoma patients.
  
  
  CONCLUSIONS
  a. injectable bromocriptine (Parlodel LAR) is a highly effective preparation particularly suitable for the long-term treatment of tumourous hyperprolactinemia; b. patients with macroprolactinoma exhibit, compared with microprolactinoma patients, better responsiveness and better tolerability to injectable bromocriptine.
authors.affiliation: First Medical Clinic, University of Milan, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Maraschini
authors.forename: M
authors.initials: M
authors.lastname: Moro
authors.forename: A
authors.initials: A
authors.lastname: Masala
authors.forename: P
authors.initials: P
authors.lastname: Toja
authors.forename: S
authors.initials: S
authors.lastname: Alagna
authors.forename: A
authors.initials: A
authors.lastname: Brunani
authors.forename: P P
authors.initials: PP
authors.lastname: Rovasio
authors.forename: A
authors.initials: A
authors.lastname: Ginanni
authors.forename: I
authors.initials: I
authors.lastname: Lancranjan
authors.forename: F
authors.initials: F
authors.lastname: Cavagnini
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D015175:Prolactinoma / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D001971:Bromocriptine; D011388:Prolactin